Accessing the US Biosimilars market
Some describe it as the countdown that’s began, others as FDA breaking its silence or a US biosimilars loom. Call it whatever you want but the issuance of guidelines and regulations for biosimilars entry into the US pharma market has definitely sparked this sector banking on a multi-billion dollar biologics market going off-patent.
The inaugural World Biosimilars Congress USA 2015 will bring together biopharma developing biosimilars to talk about the strategies in entering the US and in overcoming challenges and issues to successfully launch biosimilars in the country.
Proving high bio-similarity and satisfying FDA rules
World Biosimilars Congress USA will bring together senior level executives and key decision makers from biopharma developing biosimilars to meet and discuss strategies in entering the US and in developing biosimilars cost-effectively. Case studies, panel discussions, technical showcases, inspiring keynotes with many opportunities for networking and meetings fill the two days.